FDA Section 5 \u2022 cited verbatim

Granisetron - Warnings and Precautions

The following warnings and precautions are taken directly from the US FDA-approved drug label for Granisetron. This is the same information dispensing pharmacists read.

WARNINGS Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).

Some of the reported cases were fatal.

Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagonist alone has also been reported.

The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.

Symptoms associated with serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs.

If symptoms of serotonin syndrome occur, discontinue granisetron and initiate supportive treatment.

Patients should be informed of the increased risk of serotonin syndrome, especially if granisetron is used concomitantly with other serotonergic drugs [see Drug Interactions ].

Applies to YOU?

Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 8+ warnings apply to your profile.

Ask Health AI \u2192